Rubric Capital Management (New York)’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Rubric Capital Management (New York)’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8,963,256	Closed	-$37.6M	–	80
2023 Q1	$37.6M	Buy	+8,963,256	New	+$46.5M	0.98%	29

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Rubric Capital Management (New York)'s CTIC Position: Q2 2023 in Review

Rubric Capital Management (New York) sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 8,963,256 shares — an estimated $37.6M sold.

Rubric Capital Management (New York) first reported a position in CTIC in Q1 2023 and held it in 1 quarter. The position peaked at $37.6M in Q1 2023. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Rubric Capital Management (New York) reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Rubric Capital Management (New York) sold 8,963,256 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $37.6M.
Rubric Capital Management (New York) first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2023 and held it in 1 quarter.
Rubric Capital Management (New York)'s CTI BioPharma Corp. (DE) Common Stock position peaked at $37.6M in Q1 2023.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2023, filed 11 Aug 2023.